Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities Awarded 2024 Prix Galien USA Award as “Best Startup” by the Galien Foundation BOSTON, March 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc.... Read More